Key result
Amiodarone reduced arrhythmic but not overall mortality post-myocardial infarction, while implantable cardioverter-defibrillators demonstrated superiority over amiodarone in improving overall survival.
Why the study?
Does amiodarone improve survival or reduce arrhythmic recurrence compared to other therapies or ICDs in patients with various cardiac conditions?
Population
Patients with supraventricular and ventricular tachyarrhythmias, including post-myocardial infarction…
Comparison
Amiodarone vs Other antiarrhythmic drugs, placebo, or…
Design
Review
Authors
Loading...
Supports ICD preference over amiodarone for survival in high-risk patients; leaves open optimal antiarrhythmic strategies in modern practice.
Does amiodarone improve survival or reduce arrhythmic recurrence compared to other therapies or ICDs in patients with various cardiac conditions?
This review highlights that while amiodarone reduces arrhythmic mortality in certain populations, ICD therapy is superior for overall survival in high-risk patients with ventricular tachyarrhythmias.
Naccarelli et al. (2000) conducted a review in Supraventricular and ventricular tachyarrhythmias. Amiodarone vs. ICD therapy or other antiarrhythmic drugs was evaluated. Amiodarone reduced arrhythmic but not overall mortality post-myocardial infarction, while implantable cardioverter-defibrillators demonstrated superiority over amiodarone in improving overall survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: